HopeAI, a leader in artificial intelligence (AI) for accelerating drug development, has joined the renowned Mayo Clinic Platform Accelerate program. This collaboration grants HopeAI access to Mayo Clinic's world-leading real-world data (RWD) platform to make clinical trials faster, more precise, and more reliable.
Developing new drugs is one of the greatest challenges in modern healthcare. Globally, pharmaceutical companies invest over $300 billion annually in research and development, with the process from discovery to market launch taking an average of twelve years. Clinical trials consume about 70 percent of the time and costs, yet approximately 90 percent of drug candidates fail before reaching patients. This slows the availability of new treatment options for serious diseases such as cancer, heart disease, or rare diseases and drives up healthcare costs.
HopeAI uses AI and statistical models in combination with reliable medical data to optimize clinical trial planning, select suitable patients more precisely, and increase the reliability of results. This allows promising therapies to reach patients faster and increases the probability of success. A key element is the development of AI agents in collaboration with HemOnc.org, the world's largest medical wiki platform for cancer therapies. These agents provide evidence-based recommendations, identify optimal patient groups, and minimize costly delays in trials.
Admission to the Mayo Clinic Accelerate program underscores the high quality and credibility of HopeAI. The company is now working directly with Mayo Clinic experts and their unique data resources to develop innovative solutions for healthcare. Two of the world's top ten pharmaceutical companies, as well as several innovative biotech firms, are already among HopeAI's customers, highlighting the high market demand and potential for commercial growth.
The partnership with the Mayo Clinic Platform marks a milestone for HopeAI, positioning the company at the intersection of AI, big data, and precision medicine. In a market with an annual volume of hundreds of billions of dollars, HopeAI aims to increase the efficiency of drug development and sustainably improve healthcare.
Über HopeAI
HopeAI widmet sich der Beschleunigung der klinischen Entwicklung neuer Therapien durch KI. Durch die Integration umfassender klinischer Daten mit innovativen statistischen Ansätzen optimiert HopeAI die Studiengestaltung, verbessert die Patientenrekrutierung und steigert die Erfolgswahrscheinlichkeit in der Arzneimittelentwicklung.
Weitere Informationen finden Sie unter https://hopeai.co/.
Quelle: HopeAI, Inc.
